(Q39666905)

13 September 2017

1 reference

title

Cephalosporin, carbapenem, and monobactam antibiotics (English)

1 reference

13 September 2017

main subject

carbapenem antibiotic

0 references

antibiotic

0 references

author name string

R L Thompson

series ordinal

1

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 September 1987

1 reference

13 September 2017

1 reference

13 September 2017

volume

62

1 reference

13 September 2017

issue

9

1 reference

13 September 2017

page(s)

821-834

1 reference

Clinical pharmacokinetics of the third generation cephalosporins

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

In vitro and pharmacokinetic properties of the carbapenems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Microbial resistance to newer generation beta-lactam antibiotics: clinical and laboratory implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

In vitro activity of azthreonam, a monobactam antibiotic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

In-vitro and in-vivo antibacterial activity of imipenem against clinical isolates of bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Cefuroxime in bacterial meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Treatment of 160 cases of acute bacterial meningitis with cefotaxime.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Hypoprothrombinemia caused by cephalosporins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Intestinal side effects of cefoperazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Development of resistance to -lactam antibiotics with special reference to third-generation cephalosporins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

The responsibility of the infectious disease community for the optimal use of antimicrobial agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Antimicrobial activity, bacterial resistance, and antimicrobial pharmacology. Is it possible to use new agents cost-effectively?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

The Cephalosporin Antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Factors that affect the in-vitro activity of cephalosporin antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

The new beta-lactamase-stable cephalosporins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

The cephalosporin antibiotic agents--II. First- and second-generation agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Cefamandole and cefoxitin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Third generation cephalosporins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Comparative in vitro activities of third-generation cephalosporins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Third-generation and investigational cephalosporins: I. Structure-activity relationships and pharmacokinetic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Third-Generation and Investigational Cephalosporins: II. Microbiologic Review and Clinical Summaries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Pharmacokinetic properties of the newer cephalosporins. A valid basis for drug selection?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Ceforanide: antibacterial activity, pharmacology, and clinical efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

In vitro and clinical evaluation of ceforanide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Cefotetan: in-vitro antibacterial activity and susceptibility to beta-lactamases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Cefotaxime A review of its Antibacterial Activity, Pharmacological Properties and Therapeutic Use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Cephalosporins and Related Antibiotics: An Overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

The place of cephalosporins in antibacterial treatment of infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Do we need the third-generation cephalosporins?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Ceftizoxime: a beta-lactamase-stable, broad-spectrum cephalosporin. Pharmacokinetics, adverse effects and clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Ceftizoxime and other third-generation cephalosporins: structure-activity relationships

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Ceftriaxone: a beta-lactamase-stable, broad-spectrum cephalosporin with an extended half-life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Ceftriaxone A Review of its Antibacterial Activity, Pharmacological Properties and Therapeutic Use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Moxalactam (Latamoxef) A Review of its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Treatment of bacterial meningitis with ceftizoxime

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Imipenem: first of a new class of beta-lactam antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

Clinical pharmacology of aztreonam in healthy recipients and patients: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

7 January 2021

Cross-allergenicity and immunogenicity of aztreonam.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

7 January 2021

Relation of structural properties of beta-lactam antibiotics to antibacterial activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

7 January 2021

The pharmacology of aminoglycosides--I. Considered as a group

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

7 January 2021

First and second generation cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

7 January 2021

Review of the new second-generation cephalosporins: cefonicid, ceforanide, and cefuroxime

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962336-2

1 reference

7 January 2021

10.1016/S0025-6196(12)62336-2

Identifiers

DOI

1 reference

13 September 2017

1 reference